arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Profound Medical Corp.

PROF
$5.88 ▼ -0.20 (-3.29%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
16 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

Profound Medical Corp. faces fundamental challenges with weakness in Return on Common Equity (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $213.7M
Dividend Yield
Revenue Growth 12.3%
Op. Margin -445.7%
ROIC -20.5%
FCF / Share $-0.31
Trailing P/E
Price / Book 4.3x
FCF Yield
Debt / Equity 0.09
info Valuation on last close. End-of-day price, Sep 22, 2026.

16-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.48M
↑ +12.3%
Net Income Profit after all expenses
$-7.05M
↑ +34.2%
Operating Margin Operating profit as % of sales
-445.7%
↓ -196.5% 0th
FCF / Share Free cash flow per share
$-0.31
↓ -31.9%
Long-Term Debt Long-term obligations
$4.51M
— +0.1%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
14
Financial Health
49
Cash Quality
60

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 16 quarters